Novel peptides that inhibit heparanase activation of the coagulation system

 

 Buy Article Permissions and Reprints

Summary

Heparanase is implicated in cell invasion, tumour metastasis and angiogenesis. It forms a complex and enhances the activity of the blood coagulation initiator – tissue factor (TF). We describe new peptides derived from the solvent accessible surface of TF pathway inhibitor 2 (TFPI-2) that inhibit the heparanase procoagulant activity. Peptides were evaluated in vitro by measuring activated coagulation factor X levels and co-immunoprecipitation. Heparanase protein and/or lipopolysaccharide (LPS) were injected intra-peritoneally and inhibitory peptides were injected subcutaneously in mouse models. Plasma was analysed by ELISA for thrombin-antithrombin complex (TAT), D-dimer as markers of coagulation activation, and interleukin 6 as marker of sepsis severity. Peptides 5, 6, 7, 21 and 22, at the length of 11–14 amino acids, inhibited heparanase procoagulant activity but did not affect TF activity. Injection of newly identified peptides 5, 6 and 7 significantly decreased or abolished TAT plasma levels when heparanase or LPS were pre-injected, and inhibited clot formation in an inferior vena cava thrombosis model. To conclude, the solvent accessible surface of TFPI-2 first Kunitz domain is involved in TF/heparanase complex inhibition. The newly identified peptides potentially attenuate activation of the coagulation system induced by heparanase or LPS without predisposing to significant bleeding tendency.

• References

• 1 Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 1998; 330: 1341-1350.
  CrossrefPubMedGoogle Scholar
• 2 Pikas DS, Li JP, Vlodavsky I. et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998; 273: 18770-1877.
  CrossrefPubMedGoogle Scholar
• 3 Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99-108.
  PubMedGoogle Scholar
• 4 Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341-347.
  CrossrefPubMedGoogle Scholar
• 5 Nadir Y, Brenner B, Zetser A. et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006; 04: 2443-2451.
  CrossrefPubMedGoogle Scholar
• 6 Nadir Y, Brenner B, Gingis-Velitski S. et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost 2008; 99: 133-141.
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Nadir Y, Brenner B, Fux L. et al. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 2010; 95: 1927-1934.
  CrossrefPubMedGoogle Scholar
• 8 Baker AB, Gibson WJ, Kolachalama VB. et al. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J Am Coll Cardiol 2012; 59: 1551-1560.
  CrossrefPubMedGoogle Scholar
• 9 Zcharia E, Metzger S, Chajek-Shaul T. et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004; 18: 252-263.
  CrossrefPubMedGoogle Scholar
• 10 Zcharia E, Jia J, Zhang X. et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 2009; 04: e5181.
  CrossrefPubMedGoogle Scholar
• 11 Diaz JA, Obi AT, Myers Jr DD. et al. Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 556-562.
  CrossrefPubMedGoogle Scholar
• 12 Zetser A, Levy-Adam F, Kaplan V. et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004; 117: 2249-2258.
  CrossrefPubMedGoogle Scholar
• 13 Ahamed J, Niessen F, Kurokawa T. et al. Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia. Blood 2007; 109: 5251-5259.
  CrossrefPubMedGoogle Scholar
• 14 Sprecher CA, Kisiel W, Mathewes S. et al. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353-3357.
  CrossrefPubMedGoogle Scholar
• 15 Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (02) Suppl S26-34.
  CrossrefPubMedGoogle Scholar
• 16 Nadir Y, Kenig Y, Drugan A. et al. Involvement of heparanase in vaginal and cesarean section deliveries. Thromb Res 2010; 126: e444-450.
  CrossrefPubMedGoogle Scholar
• 17 Nadir Y, Kenig Y, Drugan A. et al. An assay to evaluate heparanase procoagulant activity. Thromb Res 2011; 128: e3-8.
  CrossrefPubMedGoogle Scholar
• 18 Westergaard JG, Teisner B, Hau J. et al. Placental protein and hormone measurements in twin pregnancy. Br J Obstet Gynaecol 1985; 92: 72-76.
  PubMedGoogle Scholar
• 19 Kisiel W, Sprecher CA, Foster DC. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. Blood 1994; 84: 4384-4385.
  PubMedGoogle Scholar
• 20 Vlodavsky I, Elkin M, Abboud-Jarrous G. et al. Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 2008; 49: 207-210.
  CrossrefPubMedGoogle Scholar
• 21 Chand HS, Du X, Ma D. et al. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004; 103: 1069-1077.
  PubMedGoogle Scholar